文献速递甲状腺疾病

卡博替尼片剂60 mg/日与胶囊剂140 mg/日治疗进展性转移性甲状腺髓样癌疗效的随机双盲非劣效性研究

A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer.
PubMed 文献 · Thyroid · 2022-01-01

这项4期随机双盲非劣效性试验纳入247例进展性转移性甲状腺髓样癌患者,1:1随机接受卡博替尼片剂60 mg/日或胶囊剂140 mg/日。主要终点盲法独立影像委员会评估的无进展生存期非劣效性未达成(中位11.0个月 vs 13.9个月,HR 1.24,95%CI 0.90-1.70,p=0.19)。两组客观缓解率均为33%,片剂组不良事件、剂量减少及因不良事件停药比例较低。

要点

  • 片剂60 mg/日对比胶囊剂140 mg/日未达成无进展生存期非劣效性(HR 1.24,95%CI 0.90-1.70)。
  • 两组客观缓解率均为33%,片剂组3/4级不良事件63% vs 72%。
  • 片剂组剂量减少69% vs 81%,因不良事件停药23% vs 36%。

核心结论

  • 卡博替尼片剂60 mg/日对比胶囊剂140 mg/日未达成无进展生存期非劣效性,两组客观缓解率相同且片剂组不良事件发生率较低。

研究设计与样本

  • 4期随机双盲非劣效性试验(NCT01896479),进展性转移性甲状腺髓样癌患者1:1随机接受卡博替尼片剂60 mg/日(n=123)或胶囊剂140 mg/日(n=124),共247例。
  • 主要终点为盲法独立影像委员会按RECIST v1.1评估的无进展生存期,非劣效界值为风险比95%置信区间上限小于1.58。
  • 次要终点为盲法独立影像委员会按RECIST v1.1评估的客观缓解率,其他终点包括安全性和药代动力学。

主要发现

  • 数据截止2020年7月15日,非劣效性未达成:片剂60 mg/日组中位无进展生存期11.0个月 vs 胶囊剂140 mg/日组13.9个月(HR 1.24;95%CI 0.90-1.70;p=0.19)。
  • 两组客观缓解率均为33%。
  • 片剂60 mg/日组3/4级不良事件发生率63% vs 胶囊剂140 mg/日组72%,剂量减少69% vs 81%,因不良事件停药23% vs 36%。
  • 卡博替尼血浆浓度初期在140 mg/日组较高,后续时间点两组趋于相似。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Cabozantinib inhibits pathways involved in medullary thyroid cancer (MTC). Cabozantinib is approved as 140 mg/day in capsules for MTC and 60 mg/day in tablets for other solid tumors. This study compared the two doses in progressive metastatic MTC. Methods: In this Phase 4, randomized, double-blind noninferiority (NI) trial (NCT01896479), patients with progressive metastatic MTC were randomized 1:1 to cabozantinib 60 mg/day tablet or 140 mg/day capsules. The primary end point was progression-free survival (PFS) by blinded independent radiology committee (BIRC) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. NI would be concluded if the upper 95% confidence interval [CI] for the PFS hazard ratio (HR) was less than the NI margin, 1.58. The secondary end point was objective response rate (ORR) by BIRC per RECIST v1.1; additional end points included safety and pharmacokinetics. Results: At data cutoff (July 15, 2020), 247 patients were randomized to the 60 mg/day tablet arm (n = 123) and the 140 mg/day capsules arm (n = 124). NI was not met (median PFS 11.0 months vs. 13.9 months in the 60 and 140 mg/day arms [HR 1.24; CI 0.90-1.70; p = 0.19]). The ORR was 33% in both arms. Generally, adverse event (AE) incidence was lower in the 60 mg/day arm (Grade 3/4, 63% vs. 72%), as were dose reductions (69% vs. 81%) and treatment discontinuations due to AEs (23% vs. 36%). Initially, cabozantinib plasma concentrations were higher in the 140 mg/day arm but became similar between arms at later time points. Conclusions: PFS NI of the cabozantinib 60 mg/day tablet vs. 140 mg/day capsules was not met. The 60 mg/day tablet had the same ORR and lower rates of AEs. Clinical Trial Registry: ClinicalTrials.gov NCT01896479.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Capdevila J, Klochikhin A, Leboulleux S, et al. A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. Thyroid. 2022. PMID: 35403447. doi:10.1089/thy.2022.0027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。